Heart rate variability is severely impaired among type 2 diabetic patients with hypertension

Abstract

Diabetes appears to have a greater effect on autonomic dysfunction compared with hypertension. Patients suffering from both diabetes and hypertension are at the highest risk of reduced heart rate variability. Early assessment of the autonomic nerve function is suggested in diabetic patients with hypertension.

Effectiveness of Acarbose in Treating Elderly Patients with Diabetes with Postprandial Hypotension

“…HRV is also significantly impaired in patients with T2DM 18. In the present study, the SDs and CVs of blood pressure were positively correlated with HRV, catecholamines, and blood glucose values.…”

Why Not to Use the Handgrip Test in the Assessment of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes Mellitus?

“…Previously, both hypertension and DM were found to be associated with impaired autonomic function: they negatively influence most CARTs [28], baroreflex sensitivity and heart rate variability [29][30][31] with their effects being additive [32,33]. Nevertheless, the handgrip test seems to be the only measure of CAN being conversely affected by DM and hypertension.…”

“…The majority of patients with DM, especially those with autonomic neuropathy, have hypertension as well [30,32,36,46,47]. Most patients with DM and hypertension are treated with ACE inhibitors, while these drugs might have an effect on autonomic function as well.…”

Office orthostatic blood pressure measurements and ambulatory blood pressure monitoring in the prediction of autonomic dysfunction

“…Interestingly, heart rate variability was the least common among ABP findings, present in only 60% of the patients. Heart rate variability has been well documented in diabetes, hypertension, chronic kidney disease and conditions associated with autonomic dysfunction including in paraplegics [15–17]. Postprandial hypotension has been reported to closely relate to somatic and autonomic neuropathy and was present in 37% of the diabetic patients on ABP [18], in 83% of patients with OH 2 and in 100% of Parkinson’s disease patients [19].…”